3 Pharmaceuticals Company, Rice Exporter and Vehicle Instrument Clusters Maker Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, LT Foods and Pricol
- November 13, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Emcure Pharmaceuticals, LT Foods and Pricol: ROE of 13.8% to 20.0% and FY22 to FY26 revenue CAGR of 12.1% to 27.1%. Prices as of 12 Nov 2026.
Quick Answer
The three pharma, rice and instrument cluster stocks to watch are Emcure Pharmaceuticals, LT Foods and Pricol. Their return on equity ranges from 13.8% to 20.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 27.1%. Pricol leads on both return on equity at 20.0% and revenue growth at 27.1% a year. Prices are based on the 12 November 2026 close, and this article is educational, not investment advice.
Pharma, rice and instrument cluster stocks offer a focused view of a sector where demand keeps widening. Emcure Pharmaceuticals, LT Foods and Pricol cover a pharmaceuticals company, a rice exporter and a vehicle instrument clusters maker.
This list covers three pharma, rice and instrument cluster stocks with complete current figures: Emcure Pharmaceuticals, LT Foods and Pricol. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, Rice and Instrument Cluster Stocks?
Pharma, rice and instrument cluster stocks are listed companies that make and sell branded medicines and injectables in India and abroad, mill and export basmati and other rice, and make instrument clusters and sensors for vehicles. Their earnings depend on medicine demand, rice exports and vehicle output.
Pharma, Rice and Instrument Cluster Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 2,314.4 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| LT Foods | 432 | 13,359 | 20.9 | 33.5 | 13.8 | 0.36 |
| Pricol | 733.75 | 8,072 | 30.1 | 36.9 | 20.0 | 0.30 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing pharma, rice and instrument cluster stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma, Rice and Instrument Cluster Stocks Have a Strong Roadmap in India?
Pharma, rice and instrument cluster stocks have a strong roadmap in India because wider access to quality medicines, growing global demand for basmati and rising use of digital vehicle displays keep widening the market for these companies.
- Pharmaceuticals. Patients need quality branded medicines.
- Rice exports. Global buyers prefer premium rice.
- Instrument clusters. Vehicles carry more digital displays.
Why Emcure Pharmaceuticals Features Among These Pharma, Rice and Instrument Cluster Stocks
Among the pharma, rice and instrument cluster stocks on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why LT Foods Features Among These Pharma, Rice and Instrument Cluster Stocks
Among the branded generics, basmati exporter and dashboard shares on this list, LT Foods is a leading maker of basmati and other specialty rice, selling under brands such as Daawat and Royal in India and across global markets. It also sells organic and ready-to-heat foods.
In the June 2026 quarter, revenue grew 26.4% year on year to Rs 3,161 crore, while net profit rose 8.9% to Rs 183 crore. Revenue rose from Rs 5,451 crore in FY22 to Rs 11,023 crore in FY26, a compound annual growth rate of 19.3%.
Net profit grew from Rs 309 crore in FY22 to Rs 625 crore in FY26, which works out to a compound annual growth rate of 19.3%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 13,359 crore. The stock trades at a P/E of 20.9, below the industry P/E of 33.5.
Roadmap: The company is expanding branded sales abroad and growing its organic and ready-to-eat range. Long-standing sourcing relationships with farmers support quality and supply.
What to watch: Follow branded rice volumes, international growth and ready-to-eat sales.
Why Pricol Features Among These Pharma, Rice and Instrument Cluster Stocks
Among the three companies on this list, Pricol, based in Coimbatore, makes instrument clusters, driver information systems, sensors and pumps for two-wheelers, commercial vehicles and off-highway vehicles.
The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P/E of 30.1, below the industry P/E of 36.9.
Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%. Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore.
Roadmap: Digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.
What to watch: Track the shift to digital clusters and the progress of new product ramp-ups.
Emcure Pharmaceuticals vs LT Foods vs Pricol on Key Financials
The table below sets the three pharma, rice and instrument cluster stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| LT Foods | 5,451 | 11,023 | 19.3% | 625 | 5.7% |
| Pricol | 1,554 | 4,052 | 27.1% | 251 | 6.2% |
Pricol posts the highest return on equity in this group at 20.0%. LT Foods has the largest FY26 revenue at Rs 11,023 crore, and Pricol shows the fastest revenue growth with a 27.1% compound annual rate. A useful habit with pharma, rice and instrument cluster stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Emcure Pharmaceuticals | 2,104 | 2,583 | 22.7% |
| LT Foods | 2,501 | 3,161 | 26.4% |
| Pricol | 898 | 1,108 | 23.4% |
Key Risks to Check Before Investing in Pharma, Rice and Instrument Cluster Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, rice and instrument cluster stocks, the main points are: Long-term branded generics, basmati exporter and dashboard shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Production cycles. Vehicle output can vary with demand.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, rice and instrument cluster stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, Rice and Instrument Cluster Stocks
Pharma, rice and instrument cluster stocks reward patient research into demand, execution and financial strength. Emcure Pharmaceuticals, LT Foods and Pricol each have a clear plan to grow. Based on the 12 November 2026 close, Emcure Pharmaceuticals trades at Rs 2,314.4, LT Foods at Rs 432 and Pricol at Rs 733.75. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma, rice and instrument cluster stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma, rice and instrument cluster stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, rice and instrument cluster stocks?
Ans. Pharma, rice and instrument cluster stocks are listed companies that make and sell branded medicines and injectables in India and abroad, mill and export basmati and other rice, and make instrument clusters and sensors for vehicles. Their earnings depend on medicine demand, rice exports and vehicle output. This list looks at three of them, Emcure Pharmaceuticals, LT Foods and Pricol, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.
Which pharma, rice and instrument cluster stocks are covered in this list?
Ans. This list covers Emcure Pharmaceuticals, LT Foods and Pricol. Based on the 12 November 2026 close, Emcure Pharmaceuticals traded at Rs 2,314.4, LT Foods at Rs 432 and Pricol at Rs 733.75. Their return on equity ranges from 13.8% to 20.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.1% to 27.1%.
Why do pharma, rice and instrument cluster stocks have a strong future roadmap in India?
Ans. Pharma, rice and instrument cluster stocks have a strong roadmap in India because wider access to quality medicines, growing global demand for basmati and rising use of digital vehicle displays keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need quality branded medicines. Rice exports. Global buyers prefer premium rice. Instrument clusters. Vehicles carry more digital displays. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has LT Foods performed financially?
Ans. Revenue rose from Rs 5,451 crore in FY22 to Rs 11,023 crore in FY26, a compound annual growth rate of 19.3%. Net profit grew from Rs 309 crore in FY22 to Rs 625 crore in FY26, which works out to a compound annual growth rate of 19.3%. In the June 2026 quarter, revenue grew 26.4% year on year to Rs 3,161 crore, while net profit rose 8.9% to Rs 183 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.36 and a market capitalisation of Rs 13,359 crore. The stock trades at a P/E of 20.9, below the industry P/E of 33.5. Looking ahead, the company is expanding branded sales abroad and growing its organic and ready-to-eat range. Long-standing sourcing relationships with farmers support quality and supply.
How has Pricol performed financially?
Ans. Revenue rose from Rs 1,554 crore in FY22 to Rs 4,052 crore in FY26, a compound annual growth rate of 27.1%. Net profit grew from Rs 51.1 crore in FY22 to Rs 251 crore in FY26, which works out to a compound annual growth rate of 48.8%. In the June 2026 quarter, revenue grew 23.4% year on year to Rs 1,108 crore, while net profit rose 34.3% to Rs 67.0 crore. The company has a return on equity of 20.0%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 8,072 crore. The stock trades at a P/E of 30.1, below the industry P/E of 36.9. Looking ahead, digital clusters and connected vehicle systems carry higher value per vehicle than the analogue gauges they replace. Pricol is also expanding into electric vehicle components and exports, and widening its non-auto business to reduce cyclicality.
What risks should investors check before buying pharma, rice and instrument cluster stocks?
Ans. Investors should check a few risks before buying pharma, rice and instrument cluster stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Production cycles. Vehicle output can vary with demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, rice and instrument cluster stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
